Barclays
TGTX icon

Barclays’s TG Therapeutics TGTX Stock Holding History

Barclays’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-49,400
Closed -$879K – 5477
2024
Q2 		$879K Buy
+49,400
New +$788K ﹤0.01% 2678
2023
Q1 		– Sell
-194,100
Closed -$2.3M – 5342
2022
Q4 		$2.3M Buy
+194,100
New +$1.41M ﹤0.01% 2176

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Barclays's TGTX Position: Q2 2026 in Review

Barclays increased its TG Therapeutics (TGTX) stake by 721% in Q2 2026, buying an estimated $34.4M and bringing the position to 957,848 shares worth $52.6M. The position accounts for 0.01% of the portfolio, ranked #715.

Barclays first reported a position in TGTX in Q2 2013 and has held it in 53 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Barclays held 957,848 shares of TG Therapeutics worth $52.6M as of Q2 2026.
  • Barclays bought 841,191 TG Therapeutics shares in Q2 2026, an estimated $34.4M.
  • TG Therapeutics made up 0.01% of Barclays's portfolio in Q2 2026, its #715 holding.
  • Barclays first reported a position in TG Therapeutics in Q2 2013 and has held it in 53 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.